Öğr. Gör. ESRA TUNÇ

Yayın Ağı

Makaleler 12

1. A brief communication of patients with homozygous C282Y mutation-related hereditary hemochromatosis

GÖKCAN H., Oz D., BODAKÇİ E., TUNÇ E., İDİLMAN R.

HEPATOLOGY FORUM , cilt.5, sa.3, ss.161-164, 2024 (ESCI)

2. Chronic hepatitis delta with normal ALT and hepatitis D viremia: unravelling its natural history

Gulnar M. O., Kamal H., Palom A., Arici S., Esteban R., TUNÇ E., et al.

JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded)

3. The role of PAGE-B score in predicting the development of hepatocelular cancer in patients with chronic delta hepatitis

KESKİN O., Kalkan C., ÖZTÜRK B., Caliskan A., Sahin H., Gumussoy M., et al.

JOURNAL OF HEPATOLOGY , cilt.78, 2023 (SCI-Expanded)

4. Non-invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta

Kalkan Ç., Yılmaz Y., Erdoğan B. D., SAVAŞ B., Yurdcu E., Çalışkan A., et al.

Journal of Viral Hepatitis , cilt.30, sa.5, ss.406-416, 2023 (SCI-Expanded, Scopus)

5. FUNCTIONAL CURE WITH LONAFARNIB-BASED THERAPY IN CHRONIC HEPATITIS DELTA

Yurdaydin C., Yurdcu E., Gumussoy M., KESKİN O., Gencdal G., Akyildiz M., et al.

HEPATOLOGY , cilt.76, 2022 (SCI-Expanded, Scopus)

6. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis

Yurdaydin C., Keskin O., Yurdcu E., Caliskan A., Onem S., Karakaya F., et al.

HEPATOLOGY , cilt.75, sa.6, ss.1551-1565, 2022 (SCI-Expanded, Scopus)

7. Molecular epidemiology of Hepatitis B virus, Hepatitis C virus, and Hepatitis D virus in general population of Afghanistan

Husseini A. A., Saeed K. M. I., Yurdcu E., BOZDAYI A. M.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.31, sa.9, ss.658-666, 2020 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

8. HEV seroprevalence in blood donors in Turkey by two commercial total anti-HEV Ab ELISA kits

Yasar O., Karatayli E., Cengiz G., Kizilpinar M., Yurdcu E., ALBAYRAK DELİALİOĞLU R., et al.

JOURNAL OF MEDICAL VIROLOGY , cilt.91, sa.12, ss.2174-2181, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

9. Epidemiology of blood-borne viral infections in Afghanistan

Husseini A. A., Saeed K. M. I., Yurdcu E., SERTÖZ Ş. R., BOZDAYI A. M.

ARCHIVES OF VIROLOGY , cilt.164, sa.8, ss.2083-2090, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

10. Evaluation of the results of MOTAKK hepatitis C virus RNA genotyping and hepatitis delta virus external quality assessment programs during 2015-2016

Karatayli E., Soydemir E., Aksoy Z. B., Kizilpinar M., Kocak A. A., Karatayli S. C., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.30, sa.11, ss.957-963, 2019 (SCI-Expanded)

11. Failure of Direct-Acting Antiviral Agents Due to Incomplete Hepatitis C Virus Genotyping

Akinci E., Yurdcu E., Orkun Ozbay B., Bodur H.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL , cilt.24, sa.3, ss.96-98, 2018 (ESCI) Sürdürülebilir Kalkınma

12. Evaluation of 2015-2016 MOTAKK HBV DNA and HCV RNA External Quality Assessment National Program Results

Karatayli E., Soydemir E., Aksoy Z. B., Kizilpinar M., Altay Kocak A., Karatayli S. C., et al.

MIKROBIYOLOJI BULTENI , cilt.52, sa.4, ss.348-366, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 12

1. NATURAL HISTORY OF INACTIVE HBsAg CARRIERS: A 10-YEAR PROSPECTIVE FOLLOW-UP STUDY

Yurdaydin C., Keskin O., Yurdcu E., Yakut M., Seven G., Kabacam G., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)

2. TREATMENT DISCONTINUATION IN HBEAG-NEGATIVE CHRONIC HEPATIT B IS A VIABLE OPTION IN NON-CIRRHOTIC GENOTYPE D CHRONIC HEPATITIS B PATIENTS

ŞAH ÜNAL F. T., Keskin O., Yurdcu E., Yilmaz Y., KARAKAYA M. F., Kartal A., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri) Sürdürülebilir Kalkınma

3. 10 YILLIK PROSPEKTİF ÇALIŞMADA DÜŞÜK VİRAL YÜKLÜ HBV TAŞIYICILARI REAKTİVASYONDAN ZİYADE HBSAG KAYBETMEYE YATKINDIR.

KESKİN O., YAKUT M., YURDCU E., KALKAN Ç., AGAYEVA S., YILMAZ Y., et al.

12. ULUSAL HEPATOLOJİİ KONGRESİ, Antalya, Türkiye, 1 - 05 Mayıs 2019, (Özet Bildiri)

4. Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study

Hardtke S., Wedemeyer H., Caruntu F. A., Curescu M., Kendal Y., AKARCA U. S., et al.

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70, (Özet Bildiri)

5. HEV seroprevalence in blood donors in Turkey: Comparison of two commercial anti-HEV total Ab ELISA kit

Yasar O., Cengiz G., Karatayli E., Kizilpinar M., Yurdcu E., ALBAYRAK DELİALİOĞLU R., et al.

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70, (Özet Bildiri)

6. Comparison of the efficacy of short term and long term nucleos(t)ide analog treatment in chronic delta hepatitis

YURTAYDIN S. C., KESKİN O., KARAKAYA M. F., YILMAZ Y., ÇALIŞKAN KARTAL A., MELEKOĞLU ELLİK Z., et al.

35. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 21 Kasım 2018, (Özet Bildiri)

7. Nonnvasve Fbross Scores Are Not Useful for Predcton of Response to Treatment n Chronc Delta Hepatts

KESKİN O., YURDCU E., KALKAN Ç., ÇALIŞKAN KARTAL A., ELLİK Z., BOZDAYI A. M., et al.

AASLD LIVER MEETING 2018, San-Francisco, Kostarika, 9 - 13 Kasım 2018, (Özet Bildiri)

8. Noninvasive Fibrosis Scores Are Not Useful for Prediction of Response to Treatment in Chronic Delta Hepatitis

Keskin O., Yurdcu E., Kalkan C., Kartal A., Ellik Z., Bozdayi M., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Kostarika, 9 - 13 Kasım 2018, cilt.68, (Özet Bildiri) Sürdürülebilir Kalkınma

9. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene (R) real-time qPCR HDV RNA assay

Yurdaydin C., Idilman R., Keskin O., Kalkan C., Karakaya F. M., Caliskan A., et al.

16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), Toronto, Kanada, 14 - 17 Haziran 2018, cilt.25, ss.10, (Özet Bildiri)

10. Value of non-invasive fibrosis markers in chronic hepatitis D

Kalkan C., Karakaya F., Keskin O., Kartal A., Karatayli E., Bozdayi M., et al.

International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, Hollanda, 19 - 23 Nisan 2017, cilt.66, (Özet Bildiri)

11. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study

Yurdaydin C., Idilman R., Keskin O., Kalkan C., Karakaya M. F., Caliskan A., et al.

International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, Hollanda, 19 - 23 Nisan 2017, cilt.66, (Özet Bildiri)

12. The prenylation inhibitor lonafarnib can induce post-treatment viral clearance in patients with chronic delta hepatitis resulting in alt normalization and regression of fibrosis

Yurdaydin C., Idilman R., Kalkan C., Karakaya M. F., Caliskan A., Keskin O., et al.

International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, Hollanda, 19 - 23 Nisan 2017, cilt.66, (Özet Bildiri)

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

126

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Açık Erişim